Published online Dec 27, 2021. doi: 10.4240/wjgs.v13.i12.1696
Peer-review started: July 22, 2021
First decision: August 19, 2021
Revised: August 30, 2021
Accepted: November 1, 2021
Article in press: November 1, 2021
Published online: December 27, 2021
Processing time: 154 Days and 20.2 Hours
Liver resection and radiofrequency ablation are considered curative options for hepatocellular carcinoma, but the choice among them is still controversial, especially in cases of hepatocellular carcinoma affecting posterosuperior segments in elderly.
In literature there are few studies which focus on surgical treatments in elderly patients with hepatocellular carcinoma especially in posterosuperior segments.
To compare short and long-term outcomes between liver resection and radiofrequency ablation in elderly patients with single hepatocellular carcinoma located in posterosuperior segments.
We performed a multicentric retrospective study enrolling 77 patients with ≥ 70 years of age, from January 2009 to January 2019 in 10 European hospital centers. Patients were divided into two groups according to the treatment, liver resection or radiofrequency ablation. Preoperative, peri-operative data and long term outcomes were retrospectively analyzed and compared in both groups before propensity score matching and after propensity score matching.
After propensity score matching, 26 patients were included in each group. Operative time and overall postoperative complications were higher in the resection group compared to the ablation group. A median hospital stay was significantly longer in the resection group than in the ablation group. There was no significant differences between resection and ablation groups in terms of overall survival and disease free survival at 1, 3 and 5 years.
Radiofrequency ablation in posterosuperior segments in elderly is safe and feasible and ensures a short hospital stay, better quality of life and does not modify the overall and disease-free survival.
Radiofrequency ablation can be considered a gold standard for the treatment of single hepatocellular carcinoma located in posterosuperior segments in elderly. These results must be a starting point for future research and to ensure a higher level of evidence in clinical practice.